The clock is ticking for the stock market as the Iran war stretches into a fourth week
Stocks have been largely calm since the start of the U.S. war in Iran, but the latest headlines could signal a turn for the worse.
Trump: U.S. could end Iran military operations ‘right now’ but will continue so Iran can ‘never rebuild’
President Donald Trump’s comments followed reports that the Pentagon is sending up to 2,500 more Marines to the Middle East from San Diego.
The spring housing market is on, but mortgage rates just shot higher. Here’s what to know.
This spring’s housing market is on, but economic headwinds are pushing back most of the advantage that buyers have gained over the past year in affordability.
Elizabeth Warren demands answers on costs, economic impact of ‘illegal and reckless war’
The liberal Democratic firebrand ripped President Donald Trump, whom she said has ‘dragged the United States into an illegal and reckless war.’
Fed Governor Waller urges caution for now, says rate cuts possible later in the year
Waller said in a CNBC interview that recent developments require a more conservative approach.
Amazon acquires startup Rivr to test robots for ‘doorstep delivery’
The company expects to test ways it can use Rivr’s robots to help with “doorstep delivery” and to “improve safety outcomes” for delivery drivers.
Netanyahu says Iran is being ‘decimated’ but revolution requires ‘ground component’
Netanyahu’s comments came after President Donald Trump, speaking in the Oval Office, said earlier that he would not send U.S. troops to the Middle East.
Iran war-induced fertilizer shortage threatens Republicans in farm states ahead of midterms
Democrats are vying for competitive seats across farm country in 2026, and fertilizer shortages spurred by the Iran war give them a new affordability angle.
CNBC Sport: This year’s March Madness will test the health of Cinderella
NIL and the transfer portal have put smaller school men’s basketball runs at risk, potentially harming many positive externalities for non-Power Four universities.
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
